Below is a list of the 10 precision oncology stories that resonated most with readers during the year: 2. Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing 3. JP ...

The firm is betting that adding the G-quadruplex stabilizer to the ADC will improve outcomes in HER2-low breast cancer patients.

The firm is developing the immunotherapy IMNN-001 for treating ovarian cancer and assessing its efficacy in patients with homologous recombination deficiency.

Stories about federal funding cuts, lab test regulation, and increasing adoption of DPYD testing were the most popular among readers.

The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.

NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...

The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.

Patients submitted for consideration for treatment with GS010/Lumevoq must meet specific eligibility criteria, including the length of time since the onset of their vision loss.

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

NEW YORK – The convergence of gene-editing breakthroughs and new regulatory frameworks signaled a turning point in 2025 for getting gene therapies for rare diseases to patients. It's notoriously ...

NEW YORK – Daiichi Sankyo and AstraZeneca have begun dosing patients with HER2-expressing endometrial cancer in a Phase III trial testing whether the antibody-drug conjugate Enhertu (trastuzumab ...

Jacobio will get $100 million upfront in the deal and be entitled to an additional $1.92 billion upon meeting certain milestones related to JAB-23E73.